PepGen

PepGen

Edit info

  • Founded: 2018
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: DMD
  • Drug types: GEN
  • Lead product: PGN-ED051
  • Funding: $108M IPO Oct 2022; $112.5M Aug 2021; $45M A Dec 2020
  • Investors: RA Capital


pepgen.com

linkedin.com

job board


Business:

Peptide Conjugation Technology for Gene Delivery

Drug notes:

PGN-EDODM1 Clin1 DM1; 3 add'l RD DMD

About:

PepGen Therapeutics is creating the next generation of oligonucleotide therapies to transform treatments of neuromuscular diseases. Oligonucleotides delivered into cells can modulate RNA expression to treat disease. PepGen is using their proprietary Enhanced Delivery Oligonucleotide (EDO) platform to identify cell-penetrating peptide conjugates that improve the activity and tolerability of oligonucleotide cargo therapeutics. PepGen’s proprietary EDO peptides are engineered for optimal tissue and cell penetration and have been shown to transport oligonucleotides into many target tissues including skeletal and cardiac muscle. PepGen is generating a pipeline of oligonucleotide therapies that target the root cause of serious neuromuscular diseases.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com